Mutation Update and Review of Severe Methylenetetrahydrofolate Reductase Deficiency.

Fiche publication


Date publication

mai 2016

Journal

Human mutation

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GUEANT Jean-Louis


Tous les auteurs :
Froese DS, Huemer M, Suormala T, Burda P, Coelho D, Guéant JL, Landolt MA, Kožich V, Fowler B, Baumgartner MR

Résumé

Severe 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency is caused by mutations in the MTHFR gene and results in hyperhomocysteinemia and varying severity of disease, ranging from neonatal lethal to adult onset. Including those described here, 109 MTHFR mutations have been reported in 171 families, consisting of 70 missense mutations, 17 that primarily affect splicing, 11 nonsense mutations, seven small deletions, two no-stop mutations, one small duplication, and one large duplication. Only 36% of mutations recur in unrelated families, indicating that most are "private." The most common mutation is c.1530A>G (numbered from NM_005957.4, p.Lys510 = ) causing a splicing defect, found in 13 families; the most common missense mutation is c.1129C>T (p.Arg377Cys) identified in 10 families. To increase disease understanding, we report enzymatic activity, detected mutations, and clinical onset information (early, <1 year; or late, >1 year) for all published patients available, demonstrating that patients with early onset have less residual enzyme activity than those presenting later. We also review animal models, diagnostic approaches, clinical presentations, and treatment options. This is the first large review of mutations in MTHFR, highlighting the wide spectrum of disease-causing mutations.

Mots clés

Age of Onset, Animals, Catalytic Domain, Databases, Genetic, Disease Models, Animal, Homocystinuria, genetics, Humans, Infant, Newborn, Methylenetetrahydrofolate Reductase (NADPH2), chemistry, Muscle Spasticity, genetics, Mutation, Neonatal Screening, Psychotic Disorders, genetics

Référence

Hum. Mutat.. 2016 May;37(5):427-38